Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
810834
Phase 1 other active
Quick answer
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) for Pancreatic Ductal Adenocarcinoma (PDAC) is a Phase 1 program (other) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RIGEL PHARMACEUTICALS INC
- Indication
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Phase
- Phase 1
- Modality
- other
- Status
- active